Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Dana-Farber Cancer Institute
This research study involves blood tests to detect HPV DNA at regular time points after treatment for HPV-positive oropharyngeal squamous cell carcinoma (HPV-OPC). Participants may undergo scans based on the results of the blood tests. Study participants will also be asked to complete quality of life questionnaires periodically.
Participation in this study may last for up to 3 years. It is expected that about 150 people will take part in this research study.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants must have histologically or cytologically confirmed incident or recurrent squamous cell carcinoma of the tonsil or base of tongue (oropharynx) - includes biopsy of any lymph node with clinical evidence of an oropharynx tumor (unknown primary carcinoma in an involved cervical neck lymph node is permitted if high-risk HPV testing is positive on the involved node)
HPV-associated tumor as defined by one or more : positive p16 immunohistochemistry (\>70%) OR in situ hybridization OR PCR-based methods
Age 18 years or older
Will undergo oropharyngeal cancer treatment with curative intent
Ability to understand and the willingness to sign a written informed consent document.
Baseline positive or detectable ctHPV DNA result in plasma OR detectable corresponding HPV DNA in tumor tissue prior to treatment
You may not be if
Distant metastatic disease (M1, AJCC 8th edition)
Clareo Health | Post-treatment Surveillance in HPV+ Oropharyngeal SCC
